PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.48%
Negative EBIT growth while AGEN is at 40.73%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
3.86%
Operating income growth under 50% of AGEN's 45.68%. Michael Burry would be concerned about deeper cost or sales issues.
-1.47%
Negative net income growth while AGEN stands at 35.93%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
12.77%
EPS growth under 50% of AGEN's 36.04%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
13.49%
Diluted EPS growth under 50% of AGEN's 36.04%. Michael Burry would worry about an eroding competitive position or excessive dilution.
16.41%
Share count expansion well above AGEN's 0.24%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
17.29%
Diluted share count expanding well above AGEN's 0.24%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
23.86%
OCF growth at 50-75% of AGEN's 32.34%. Martin Whitman would question if the firm lags in monetizing sales effectively.
23.57%
FCF growth 75-90% of AGEN's 29.13%. Bill Ackman might push for improved capital allocation or operational changes to match the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21198.65%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-19211.55%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-43.46%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-15978.83%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-50766.69%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
48.21%
Positive short-term CAGR while AGEN is negative. John Neff would see a clear advantage in near-term profit trajectory.
19776.75%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
4394.26%
Positive 5Y equity/share CAGR while AGEN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
625.15%
Positive short-term equity growth while AGEN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.51%
Positive asset growth while AGEN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
8.68%
Positive BV/share change while AGEN is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
-31.37%
Our R&D shrinks while AGEN invests at 20.36%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
108.24%
SG&A growth well above AGEN's 6.94%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.